- Hemopneumothorax as an Unusual and Delayed Complication of Coronavirus Disease 2019 Pneumonia: A Case Report
-
Sayan M, Turk MS, Ozkan D, Kankoc A, Tombul I, Celik A
- KMID: 2523187
- J Chest Surg.
- 2021 Dec;54(6):521-523.
- doi: 10.5090/jcs.20.149
The increasing number of studies published on coronavirus disease 2019 (COVID-19) pneumonia has improved our knowledge of the disease itself and its complications. Despite a considerable number of publications on... -
- CITED
-
- Close
- SHARE
-
- Close
- Survival Effect of Complete Multimodal Therapy in Malignant Pleural Mesothelioma
-
Sayan M, Bas A, Turk MS, Ozkan D, Celik A, Kurul , Tastepe AI
- KMID: 2533513
- J Chest Surg.
- 2022 Oct;55(5):405-412.
- doi: 10.5090/jcs.22.037
Background: Malignant pleural mesothelioma (MPM) is an aggressive pleural malignancy, and despite all multimodal treatment modalities, the 5-year overall survival rate of patients with MPM is less than 20%. In... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical management of uveal melanoma: a comprehensive review with a treatment algorithm
-
Sayan M, Mamidanna S, Oncel D, Jan I, Vergalasova I, Weiner J, Ohri N, Acikalin B, Chundury A
- KMID: 2506931
- Radiat Oncol J.
- 2020 Sep;38(3):162-169.
- doi: 10.3857/roj.2020.00318
Uveal melanoma (UM), the most frequently occurring non-cutaneous melanoma and most common primary intraocular malignancy in adults, arises from the melanocytes of the choroid in approximately 95% of cases. Prompt... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Analysis of Primary Pulmonary Malignant Mesenchymal Tumors Treated Surgically
-
Sayan M, Kankoc A, Ozkan D, Celik A, Kurul IC, Tastepe AI
- KMID: 2521106
- J Chest Surg.
- 2021 Oct;54(5):356-360.
- doi: 10.5090/jcs.21.032
Background: Primary pulmonary malignant mesenchymal tumors are rare, constituting only 0.4% of all lung cancers. Since sarcomas are chemo/radio-resistant, surgical resection is the optimal treatment choice for patients with suitable... -
- CITED
-
- Close
- SHARE
-
- Close
- Daily localization of partial breast irradiation patients with three-dimensional ultrasound imaging
-
Sayan M, Vergalasova I, Hard D, Wrigth H, Archambault J, Gagne H, Nelson C, Heimann R
- KMID: 2468734
- Radiat Oncol J.
- 2019 Dec;37(4):259-264.
- doi: 10.3857/roj.2019.00052
PURPOSE: Accurate localization of the lumpectomy cavity during accelerated partial breast radiation (APBR) is essential for daily setup to ensure the prescribed dose encompasses the target and avoids unnecessary irradiation... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term cosmesis following a novel schedule of accelerated partial breast radiation in selected early stage breast cancer: result of a prospective clinical trial
-
Sayan M, Hard D, Wilson K, Nelson C, Gagne H, Rubin D, Heimann R
- KMID: 2401786
- Radiat Oncol J.
- 2017 Dec;35(4):325-331.
- doi: 10.3857/roj.2017.00171
PURPOSE: There is controversy regarding the cosmetic outcome after accelerated partial breast radiation (APBR). We report the cosmetic outcome from a single-arm prospective clinical trial of APBR delivered using intensity-modulated... -
- CITED
-
- Close
- SHARE
-
- Close
- A novel schedule of accelerated partial breast radiation using intensity-modulated radiation therapy in elderly patients: survival and toxicity analysis of a prospective clinical trial
-
Sayan M, Wilson K, Nelson C, Gagne H, Rubin D, Heimann R
- KMID: 2401797
- Radiat Oncol J.
- 2017 Mar;35(1):32-38.
- doi: 10.3857/roj.2016.01963
PURPOSE: Several accelerated partial breast radiation (APBR) techniques have been investigated in patients with early-stage breast cancer (BC); however, the optimal treatment delivery techniques remain unclear. We evaluated the feasibility... -
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation of response to stereotactic radiosurgery in patients with radioresistant brain metastases
-
Sayan M, Zoto Mustafayev T, Sahin B, Kefelioglu ESS, Wang SJ, Kurup V, Balmuk A, Gungor G, Ohri N, Weiner J, Ozyar E, Atalar B
- KMID: 2468735
- Radiat Oncol J.
- 2019 Dec;37(4):265-270.
- doi: 10.3857/roj.2019.00409
PURPOSE: Renal cell carcinoma (RCC) and melanoma have been considered ‘radioresistant’ due to the fact that they do not respond to conventionally fractionated radiation therapy. Stereotactic radiosurgery (SRS) provides high-dose... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of symptomatic radiation necrosis after stereotactic radiosurgery and clinical factors for treatment response
-
Sayan M, Mustafayev TZ, Balmuk A, Mamidanna S, Kefelioglu ESS, Gungor G, Chundury A, Ohri N, Karaarslan E, Ozyar E, Atalar B
- KMID: 2506933
- Radiat Oncol J.
- 2020 Sep;38(3):176-180.
- doi: 10.3857/roj.2020.00171
Purpose: Approximately 10% of patients who received brain stereotactic radiosurgery (SRS) develop symptomatic radiation necrosis (RN). We sought to determine the effectiveness of treatment options for symptomatic RN, based on... -
- CITED
-
- Close
- SHARE
-
- Close
